Supernus Pharmaceuticals | SUPN - Należności Handlowe





Należności Handlowe Zmiana Data
Abbott USD 10.4B 166M 2025-09
ANI Pharmaceuticals USD 281.08M 28.46M 2025-12
Aurora Cannabis CAD 48.26M 1.53M 2025-12
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Canopy Growth CAD 140.42M 113.56M 2025-12
Cara Therapeutics USD 2.24M 2.26M 2025-03
Corcept Therapeutics USD 59.79M 9.84M 2025-12
Eisai JPY 249.06B 25B 2025-12
Eli Lilly USD 19.46B 2.25B 2025-09
Novo Nordisk DKK 95.05B 2.4B 2025-12
Pacira USD 124.07M 8.8M 2025-12
Perrigo USD 612.8M 31.6M 2025-12
Pfizer USD 18.12B 2.02B 2025-09
Supernus Pharmaceuticals USD 187.8M 16.55M 2025-12
United Therapeutics USD 350.2M 52.5M 2025-12
Xeris Pharmaceuticals USD 51.05M 2.7M 2025-12